Genetic and Inflammatory Factors as Predictors of Progression in Nondilated Left Ventricular Cardiomyopathy
The interplay of genetics significantly influences the forecasting of deteriorating left ventricular ejection fraction (LVEF), which can lead to a transition into a dilated cardiomyopathy (DCM) phenotype, alongside a combined endpoint involving both conditions.
A striking finding from a comprehensive multicenter study published in the Canadian Journal of Cardiology reveals that nearly 40% of patients diagnosed with nondilated left ventricular cardiomyopathy (NDLVC) experienced significant disease progression during long-term monitoring. This research, involving a substantial cohort, sheds much-needed light on a patient population that has historically lacked longitudinal data.
To arrive at these findings, the researchers evaluated the outcomes of 432 adults who were treated for NDLVC at two prominent cardiomyopathy centers in Italy from 2010 to 2023. Throughout a median follow-up period of 77 months, results indicated that 38% of participants encountered adverse echocardiographic changes, characterized by:
- Worsening LVEF: 118 individuals (27.3%) faced a decline in their LVEF.
- Progression to DCM: 125 patients (28.9%) transitioned to a DCM phenotype.
- Combined Adverse Outcomes: 79 patients (18.3%) met a combined endpoint involving both a decline in LVEF and ventricular dilation.
The term NDLVC was formally included in the latest 2023 guidelines issued by the European Society of Cardiology. It pertains to patients exhibiting nonischemic myocardial scarring or dysfunction without accompanying left ventricular dilation. The authors emphasize that this study is pioneering in detailing the temporal dynamics of NDLVC, highlighting its significance given the diverse nature of the patient population affected by this condition.
Identifying Key Predictors of Disease Progression
Utilizing a multiparametric approach that encompasses clinical histories, electrocardiography, imaging techniques, and genetic data, the researchers identified several baseline characteristics that markedly predict disease progression. The most pronounced risk profile involved the presence of pathogenic or likely pathogenic genetic variants along with biopsy- or cardiac magnetic resonance–confirmed myocardial inflammation, which they labeled a genetic and inflammatory etiology.
In their multivariable analyses, the following initial characteristics were significantly associated with negative outcomes:
1. The combination of genetic and inflammatory etiologies.
2. A family history indicating cardiomyopathy or sudden cardiac death.
3. Intraventricular conduction delays observed on electrocardiograms.
4. Echocardiographic LVEF measurements falling below 45%.
5. Ring-like late gadolinium enhancement noted on cardiac MRI.
6. Instances of nonsustained ventricular tachycardia.
The study revealed that predictive models which included these factors showed exceptional discriminative ability for forecasting:
- LVEF Decline: Area under the curve (AUC) of 0.8 (95% CI, 0.75-0.86).
- Transition to DCM: AUC of 0.78 (95% CI, 0.73-0.84).
- Combined Endpoint: AUC of 0.84 (95% CI, 0.79-0.89).
Genetic Factors Linked to Reduced Risk
Interestingly, genetics alone proved to be a crucial element in risk assessment. Patients who had negative results in genetic testing demonstrated significantly lower risks for:
- Declining LVEF: Odds ratio (OR) of 0.2 (95% CI, 0.1-0.4; P < .001).
- Development of DCM: OR of 0.2 (95% CI, 0.1-0.4; P < .001).
- Combined Endpoint: OR of 0.1 (95% CI, 0.04-0.3; P < .001).
Notably, among those whose baseline LVEF was preserved (≥ 50%), none of the individuals who tested negative genetically experienced the combined endpoint throughout the follow-up period.
The researchers remarked, "Our cohort data corroborate recent literature concerning arrhythmogenic cardiomyopathy, indicating that a negative genetic test's protective effect on disease progression was more predictive than the adverse effects associated with high-risk genotypes, particularly within the subgroup exhibiting baseline LVEF ≥ 50%."
Beyond merely echocardiographic alterations, adverse remodeling was linked to poorer clinical outcomes, including increased rates of all-cause mortality, heart transplants, and significant arrhythmic events. The authors advocate for the early identification of high-risk individuals within this newly classified cardiomyopathy category to improve patient outcomes.
In conclusion, while these promising findings pave the way for enhanced understanding and management of NDLVC, the researchers stress the necessity for external validation through independent cohorts and prospective studies with extended follow-up periods to gain deeper insights into the longitudinal progression of this newly recognized and heterogeneous group of cardiomyopathies.
